During the past decade, Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE) conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 6 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Gan and Lee Pharmaceuticals, USA" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Anji Pharma" with 1 trials sponsored and "Kowa Research Institute, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" are "Type 2 Diabetes Mellitus" (3 trials), "Cardiovascular Disease" (2 trials), "Diabetes Mellitus, Type 1" (2 trials), "Diabetes Mellitus, Type 2" (2 trials) and "Type 1 Diabetes Mellitus" (2 trials). Many other conditions were trialed in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" in a lesser frequency.

Most popular intervention types in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" are "Drug" (15 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Tirzepatide" (5 trials), "Insulin Degludec" (4 trials), "Dulaglutide" (2 trials) and "Insulin Efsitora Alfa" (2 trials). Other intervention names were less common.

The vast majority of trials in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE), 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE), 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".